Monika Belickova
0000-0002-9158-881X
Institute of Hematology and Blood Transfusion
79 papers found
Refreshing results…
RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS
Low Plasma Citrate Levels and Specific Transcriptional Signatures Associated with Quiescence of CD34+ Progenitors Predict Azacitidine Therapy Failure in MDS/AML Patients
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
Modulation of the Immune Response by Deferasirox in Myelodysplastic Syndrome Patients
LncRNA Profiling Reveals That the Deregulation of H19, WT1-AS, TCL6, and LEF1-AS1 Is Associated with Higher-Risk Myelodysplastic Syndrome
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
Circulating Small Noncoding RNAs Have Specific Expression Patterns in Plasma and Extracellular Vesicles in Myelodysplastic Syndromes and Are Predictive of Patient Outcome
The formation of a somatic mutation in the HLA‐B gene throughout the development of the disease from severe aplastic anaemia to acute myeloid leukaemia
Genetic Variant Screening of DNA Repair Genes in Myelodysplastic Syndrome Identifies a Novel Mutation in the XRCC2 Gene
Cooccurring JAK2 V617F and R1063H mutations increase JAK2 signaling and neutrophilia in myeloproliferative neoplasms
Lenalidomide treatment in lower risk myelodysplastic syndromes—The experience of a Czech hematology center. (Positive effect of erythropoietin ± prednisone addition to lenalidomide in refractory or relapsed patients)
Hemoglobinopathies.
Differential expression of homologous recombination DNA repair genes in the early and advanced stages of myelodysplastic syndrome
Differential Expression of the Homologous Recombination DNA Repair Genes in Early and Advanced Stages of Myelodysplastic Syndrome
Microarray profiling defines circulating microRNAs associated with myelodysplastic syndromes
Frequency and Clinical Impact of Cytogenetic Clonal Evolution in Myelodysplastic Syndromes (MDS) with Isolated Del(5q)
Mutational Screening for Predictive Profiles of Progression in Myelodysplastic Syndrome
Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes
Application of interphase fluorescence in situ hybridisation for the analysis of CD34+ cells in peripheral blood of patients with myelodysplastic syndromes | Využití interfázní fluorescenční in situ hybridizace pro analýzu CD34+ buněk v periferní krvi u nemocných s myelodysplastickými syndromy
The Incidence and Clinical Implications of Chromothripsis in Bone Marrow Cells of Patients With Myelodysplastic Syndromes (Mds)
Missing publications? Search for publications with a matching author name.